Current situation survey and risk factors of vancomycin-associated acute kidney injury in older patients

Kun-ming PAN,Ling-yun MA,Qian XIANG,Ying ZHOU,Li YANG,Yi-min CUI

2017-01-01

Abstract:Objective:This study was to investigate the current situation and identify the risk factors of vancomycin (VAN)-associated acute kidney injury (VA-AKI) in older patients,as well as to comprehensively examine the risk related to concurrent drug use.Further,we examined the outcomes of VA-AKI patients and risk factors for these outcomes.Finally,we aimed to provide suggestions for preventing and treating VA-AKI.Methods:We conducted a retrospective observational study in older inpatients who had been treated with VAN between January 2013 and December 2013 in Peking University First Hospital.The definition of AKI was an increase in SCr levels by ≥0.3 mg·dL-1 (≥26.5 μmol·L-1) within 48 hours,or to ≥ I.5 times the baseline level certainly or presumably within the past 7 days.The definition of VI-AKI was development of AKI during VAN treatment or within 7 days following termination of VAN treatment.We compared the NO-AKI group,which did not develop AKI during or after VAN treatment,with the VI-AKI group.Results:Of 186 patients who fulfilled the inclusion and exclusion criteria,55 developed VI-AKI (29.6％).Of the patients,16.1％ received therapeutic drug monitoring (TDM) during VAN therapy.Logistic regression revealed the length of VAN therapy [odds ratio (OR) =1.022;P =0.000],simultaneous vasopressor therapy (OR =3.139;P =0.009),and simultaneous use of diuretics (OR =6.609;P =0.005) as independent risk factors for VA-AKI.Conclusion:Patients using VAN received insufficient therapeutic drug monitoring.We need to pay more attention to the patients with a long VAN therapy,simultaneous vasopressor therapy and simultaneous use of diuretics.